Cargando…

Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms

Detalles Bibliográficos
Autores principales:	Brecqueville, M, Cervera, N, Adélaïde, J, Rey, J, Carbuccia, N, Chaffanet, M, Mozziconacci, M J, Vey, N, Birnbaum, D, Gelsi-Boyer, V, Murati, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3255245/ https://www.ncbi.nlm.nih.gov/pubmed/22829192 http://dx.doi.org/10.1038/bcj.2011.31

Ejemplares similares

Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes
por: Brecqueville, M, et al.
Publicado: (2011)

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification
por: Cervera, N, et al.
Publicado: (2017)

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
por: Gelsi-Boyer, Véronique, et al.
Publicado: (2012)

Myeloid malignancies: mutations, models and management
por: Murati, Anne, et al.
Publicado: (2012)

Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
por: Rocquain, Julien, et al.
Publicado: (2010)

Multicolour-banding fluorescence in situ hybridisation (mbanding-FISH) to identify recurrent chromosomal alterations in breast tumour cell lines
por: Letessier, A, et al.
Publicado: (2005)

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia
por: Collette, Y, et al.
Publicado: (2015)

Erythroleukemia: Classification
por: Cervera, Nathalie, et al.
Publicado: (2023)

Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes
por: Devillier, Raynier, et al.
Publicado: (2015)

Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
por: Gelsi-Boyer, Véronique, et al.
Publicado: (2008)

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
por: Collignon, A., et al.
Publicado: (2020)

Polycomb group protein Suz12 is regulated by a novel miRNA-like small RNA
por: Penfornis, Patrice, et al.
Publicado: (2018)

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms
por: Tripodi, Joseph, et al.
Publicado: (2010)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
por: Ma, Wanlong, et al.
Publicado: (2010)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021)

Prognostic Value of Polycomb Proteins EZH2, BMI1 and SUZ12 and Histone Modification H3K27me3 in Colorectal Cancer
por: Benard, Anne, et al.
Publicado: (2014)

Examining disease boundaries: Genetics of myelodysplastic/myeloproliferative neoplasms
por: Hochman, Michael J., et al.
Publicado: (2021)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

The microenvironment in myeloproliferative neoplasm
por: Méndez-Ferrer, Simón, et al.
Publicado: (2018)

Spleen in myeloproliferative neoplasms
por: Barosi, Giovanni
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study
por: Ianotto, Jean-Christophe, et al.
Publicado: (2018)

Deactylase inhibition in myeloproliferative neoplasms
por: Mithraprabhu, Sridurga, et al.
Publicado: (2010)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Calreticulin Mutations in Myeloproliferative Neoplasms
por: Lavi, Noa
Publicado: (2014)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Molecular pathogenesis of the myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2021)

Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma
por: Cho, Yong Jin, et al.
Publicado: (2018)

Deregulated expression of microRNA-200b/c and SUZ12, a Polycomb repressive complex 2 subunit, in chemoresistant colorectal cancer cells
por: San, KayKay, et al.
Publicado: (2017)

Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
por: Person, Fermin, et al.
Publicado: (2021)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6–LYN gene fusion
por: Telford, N, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lgdq7f7rhdd6cdij6tcpp29si1